Bicara Therapeutics (BCAX) Net Income towards Common Stockholders (2023 - 2026)
Bicara Therapeutics (BCAX) reported Net Income towards Common Stockholders of -$56.2 million for Q1 2026, down 52.56% on a YoY basis from -$118.5 million in Q1 2025, and down 50.35% quarter-over-quarter from -$37.4 million in Q4 2025.
Bicara Therapeutics (BCAX) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
Bicara Therapeutics has reported Net Income towards Common Stockholders for 4 years, with the latest figure at -$56.2 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 52.56% year-over-year to -$56.2 million; the trailing twelve-month figure through Mar 2026 stood at -$157.3 million (down 70.38% YoY), and the FY2025 full-year result was -$138.0 million, down 102.88% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$56.2 million, down from -$37.4 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$12.4 million in Q4 2023, with the low at -$56.2 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$27.0 million across 4 years, with a median of -$22.8 million in 2023.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders increased 23.48% — and 2025, when it sank 194.58%.
- Bicara Therapeutics' Net Income towards Common Stockholders stood at -$12.4 million in 2023, then sank by 68.46% to -$21.0 million in 2024, then plunged by 78.39% to -$37.4 million in 2025, then slumped by 50.35% to -$56.2 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$56.2 million (Q1 2026), -$37.4 million (Q4 2025), and -$36.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Bicara Therapeutics | 1.31 Bn | 1.31 Bn | - | -56.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.21 Mn |
| Dec 31, 2025 | -37.39 Mn |
| Sep 30, 2025 | -36.33 Mn |
| Jun 30, 2025 | -27.39 Mn |
| Mar 31, 2025 | -36.85 Mn |
| Dec 31, 2024 | -20.96 Mn |
| Sep 30, 2024 | -17.48 Mn |
| Jun 30, 2024 | -17.05 Mn |
| Mar 31, 2024 | -12.51 Mn |
| Dec 31, 2023 | -12.44 Mn |
| Sep 30, 2023 | -22.85 Mn |